BACKGROUND: DNA methylation analysis currently requires complex multistep procedures based on bisulfite conversion of unmethylated cytosines or on methylationsensitive endonucleases. To facilitate DNA methylation analysis, we have developed a quantitative 1-step assay for DNA methylation analysis.
Methylation of DNA cytosines in the context of CpG dinucleotides is a hallmark of the epigenetic regulation of gene expression and is involved in X-chromosome inactivation, imprinting, suppression of repetitive elements, and carcinogenesis (1, 2 ) . Accordingly, analysis of DNA methylation is indispensable in both research and diagnostics, particularly considering that methylated DNA is chemically stable and is less subject to transient alterations due to biological variation than protein and mRNA (3 ) .
Most methods that have been proposed for DNA methylation analysis of specific loci are based on treating genomic DNA with sodium bisulfite, which converts cytosines, but not 5-methylcytosines, to uracil. After PCR amplification, converted cytosines are distinguished from unconverted cytosines by several methods, including bisulfite sequencing (4, 5 ) , methylation-specific PCR (6 ), high-resolution melting analysis (7 ) , pyrosequencing (8 ) , and MALDI-TOF mass spectrometry (9, 10 ) . Bisulfite-based approaches allow assessment of the methylation status for virtually any cytosine; however, the complex structure of the converted genome impedes a straightforward assay design (11 ) . Moreover, inconsistent PCR amplification of methylated and unmethylated DNA and incomplete conversion of unmethylated cytosines can hamper quantitative analyses (8, 12 ) .
As an alternative to bisulfite-based methods, quantitative analysis of DNA methylation with quantitative real-time PCR (qPCR) 4 has recently been proposed (13, 14 ) . After the digestion of DNA with methylation-sensitive endonucleases, the proportion of uncut (and thus methylated) DNA molecules is quantified by qPCR, with undigested DNA used as a reference. Additionally, methylation-dependent restriction enzymes can be used in a complementary manner, and an extrinsic DNA molecule can be spiked into the DNA preparation to evaluate whether the DNA digestion is thorough (13, 14 ) . Methylationsensitive multiplex ligation-dependent probe amplification is also based on restriction of DNA with methylation-sensitive endonucleases, but it relies on hybridization, ligation, and amplification of locusspecific probes to detect uncut molecules. This approach allows analysis of up to 40 loci in a single reaction but is hampered by reduced flexibility and precision compared with qPCR analysis of DNA methylation (15 ) .
Among the imprinting disorders, Prader-Willi syndrome (PWS) (MIM 176270) is characterized by decreased fetal and neonatal activity, severe neonatal hypotonia, and hypogenitalism (16 ) . PWS is caused mainly by the loss of the paternal allele at chromosomal region 15q11.2-13 because of interstitial deletions or maternal uniparental disomy (UPD) (70% and 30% of cases, respectively). Loss of the maternal allele at 15q11.2-13, on the other hand, causes Angelman syndrome (AS) (MIM 105830), which is characterized by mental retardation, seizures, apparent happy behavior, and ataxia of gait. In addition to maternal deletions (70% of cases) or paternal UPD (5%) at 15q11.2-13, sequence variants of the UBE3A 5 (ubiquitin protein ligase E3A) gene have been shown to be a cause of AS. Only the maternal allele is methylated at 2 distinct regions of 15q11.2-13-PW71 and the promoter region of the SNRPN (small nuclear ribonucleoprotein polypeptide N) gene. This feature allows the molecular diagnosis of PWS and AS via analysis of a patient's DNA methylation pattern. PWS patients will demonstrate full methylation, whereas these regions will be unmethylated in AS patients. These aberrant methylation patterns arise mainly because of the aforementioned deletions or UPD. In 2%-4% of PWS and AS cases, however, they are due to imprinting defects that are caused, for example, by microdeletions in the socalled imprinting center (17 ) . Both bisulfite-based methods (8, 18, 19 ) and endonuclease-based methods (14, 20 ) have been proposed for diagnosing imprinting disorders such as PWS and AS; however, these procedures consist of multiple steps and are timeconsuming. With commercial kits, bisulfite conversion still requires Ͼ3 h, and endonuclease-based approaches are hampered by extensive overnight incubations. In addition, both types of procedures require considerable hands-on time and have increased risks of handling and pipetting errors.
In the current study, we established the first quantitative 1-step DNA methylation assay (qOSMA) by combining rapid methylation-sensitive DNA digestion and qPCR in a single, closed-tube reaction. Reactions contain both methylation-sensitive FastDigest HpaII (Fermentas Life Sciences) and qPCR reagents, and DNA digestion is followed by endonuclease inactivation and qPCR. Performing sham reactions containing no endonuclease in parallel provides an estimate of DNA input and allows quantification of the number of cut (i.e., unmethylated) DNA molecules. Such data in turn permit conclusions about the methylation status of the locus of interest. To test the feasibility of our approach, we applied the method to the SNRPN locus ( Fig. 1A) (13 ) . Also measured in every individual was the unmethylated promoter of the CFTR [cystic fibrosis transmembrane conductance regulator (ATPbinding cassette sub-family C, member 7)] gene (21 ) , which served simultaneously as a control for DNA digestibility and as a reference locus for copy number assessment. In addition, including a calibrator DNA with a known methylation and copy number status in every experiment allows a functionality test for the methylation assays. The calibrator DNA also serves as a calibrator for copy number assessment (Fig. 1B) . Values for ⌬⌬C q (where C q is the quantification cycle) of the locus of interest and the reference locus, as well as of the sample to be investigated and the calibrator sample, are used to quantify copy number, as has previously been described (22, 23 ) .
We took advantage of this novel assay to simultaneously assess methylation and the copy number status of the SNRPN promoter, thereby allowing the diagnosis and molecular characterization of PWS and AS in Ͻ90 min after DNA extraction. In addition, we propose a model for correcting for reduced DNA digestibility from data obtained with the reference locus. We confirmed that this model significantly (P Ͻ 0.05) increases the assay's accuracy and permits analysis of DNA samples with reduced digestibility.
Materials and Methods

DNA SAMPLES
DNA samples from PWS and AS patients and from unaffected control individuals had previously been extracted from blood by standard procedures, including phenol-chloroform extraction and use of the QIAamp DNA Blood Midi Kit (Qiagen). Older DNA samples had become partially viscous after long-term storage. Samples with reduced digestibility were reextracted with the QIAmp DNA Micro Kit (Qiagen). To investigate the influence of DNA molecular weight, we sheared DNA before analysis by passing it up to 60 times through a 25-gauge needle.
To evaluate our novel assay as a diagnostic tool for PWS and AS, we conducted a blinded analysis of DNA samples from 12 PWS patients (10 with a deletion, 2 with UPD), 12 AS patients (9 with a deletion, 3 with UPD), and 11 unaffected control individuals. The initial diagnoses and molecular characterizations of PWS and AS were based on methylation-specific PCR followed by denaturing HPLC and microsatellite analysis (16, 24, 25 ) .
Patients and control individuals gave written informed consent for the use of their DNA for medical research; all samples were irreversibly anonymized before qOSMA analyses.
1-STEP DNA DIGESTION AND qPCR
HpaII reactions contained 0.3 U FastDigest HpaII (Fermentas), 0.8ϫ SYBR Premix Ex Taq (Perfect Real Time™) (Takara Bio), 5 nmol/L of each primer, and 12 ng genomic DNA in a final volume of 10 L. For sham reactions, HpaII was replaced by a diluent containing 10 mmol/L Tris, 100 mmol/L NaCl, 1 mmol/L dithiothreitol, 0.1 nmol/L EDTA, 200 g/L BSA, and 500 mL/L glycerol. Primer sequences for the SNRPN promoter were 5Ј-CATCTGTCTGAGGAGCGGTC-3Ј (forward) and 5Ј-TCCAGAACAAAGGACTTTAGGG-3Ј (reverse), and primer sequences for the CFTR promoter were 5Ј-CGAAGGAGGGTCTAGGAAGC-3Ј (forward) and 5Ј-CGATTCTGACTCCCAGCCTC-3Ј (reverse). These primers produced amplicons spanning 1 and 3 HpaII sites in the SNRPN and CFTR genes, respectively. Reactions were performed on capillarybased LightCyclers (Roche Applied Science) under the following conditions: 10 min at 37°C (DNA digestion), 5 min at 95°C (HpaII inactivation, Taq polymerase activation), and 40 cycles of 95°C for 10 s, 60°C (SNRPN) or 65°C (CFTR) for 15 s, and 72°C for 15 s. In the blinded analysis of PWS and AS samples, the annealing temperature for the CFTR assay was decreased to 60°C (same as the SNRPN assay). This change allowed PWS/AS diagnosis to be performed on 
DATA ANALYSIS
C q s were evaluated with the default second derivative maximum method of the LightCycler system, and the means of duplicate measurements were used for calculations. The degree of methylation of each locus was assigned according to Eq. 1:
where C qHpaII and C qsham are the C q s of the reactions performed with and without HpaII, respectively. For the assessment of assay performance, measured methylation levels Ͼ100% were not adjusted to 100% in this study. Similarly, methylation levels Ͻ0% (i.e., occurring after correction for incomplete digestion; see below) were not adjusted to 0%. If the measured methylation level of the CFTR promoter was Ͻ15% in the blinded analysis, the DNA digestion was considered to be thorough, and measured methylation levels of the SNRPN promoter were used to distinguish PWS patients (Ͼ85% methylated), AS patients (Ͻ15% methylated), and healthy control individuals (35%-65% methylated).
The ⌬⌬C q method was used to evaluate the copy number status of the SNRPN promoter (27 ) , as outlined in Eq. 2:
Copy number ratio
where C qpat is the Cq obtained with the sham reaction of the patient or sample of interest (pat) and C qcal is the C q obtained with the calibrator (cal). Samples with copy number ratios Ͻ0.65 were considered to carry a deletion, whereas ratios between 0.85 and 1.15 were considered evidence of the presence of 2 SNRPN copies, indicating a UPD or an imprinting defect in cases with an aberrant methylation pattern at the SNRPN locus. All calculations were done with R (28 ) and Microsoft Excel software. Results are reported as the median (range).
BIAS CORRECTION FOR INCOMPLETE DIGESTION
In some instances, it might be of interest not only to detect but also to correct for incomplete DNA digestion (e.g., if only DNA with reduced digestibility is available for specific samples). To correct for such incompletion, one might subtract the level of methylation measured at an unmethylated reference locus (CFTR in the present study) from the level of methylation measured for the locus of interest (SNRPN in the present study), as calculated with Eq. 3:
where CSML 1 is the corrected SNRPN methylation level and the MM terms represent the uncorrected, locus-specific measured methylation values as calculated with Eq. 1. This equation corrects for the proportion of DNA molecules that are not digestible in a given sample. This model, however, does not correct for assayspecific falsifications in methylation measurements that might be inherent in a given assay or might arise because of assay variation between experiments. For example, the CFTR assay yielded higher measured methylation levels than the SNRPN assay, even when equivalent methylation was expected (see Discussion). To correct for such greater-than-expected methylation, one might include a calibrator with known methylation levels, thereby allowing modulation of the subtracted methylation levels of the reference locus according to assayspecific falsifications, as described by Eq. 4:
where CSML is the corrected SNRPN methylation level and the MM terms represent the uncorrected, locusspecific measured methylation values as calculated with Eq. 1. When Eq. 4 is applied to a sample with a high SNRPN methylation level (such as from a PWS patient), however, a correction is inappropriate, because the measurement of the SNRPN locus is not affected by reduced digestibility-simply because no digestion occurs with 100% methylation. It would thus be appropriate if the correction factor described in Eq. 4 had more power at low methylation levels, because low levels need more correction. Therefore, results obtained with Eq. 4 provide a raw estimate of DNA methylation, which is then included in a weighting factor for correction, as described by Eq. 5:
Results
ASSAY ESTABLISHMENT AND EVALUATION
Mixing experiments with PWS and AS DNA were performed to assess whether the SNRPN assay shows a linear response to various degrees of methylation. The measured degree of methylation did not deviate more than 5.9% from the expected one, for a coefficient of determination (r 2 ) of 0.997 ( Fig. 2A) . To assess the influence of DNA concentration on methylation measurements, we varied the input from 1 ng to 81 ng DNA per 10-L reaction. Fig. 3A demonstrates that different Results were obtained with the SNRPN assay and with DNA from AS patients (Ⅲ, 0% methylation expected), unaffected control individuals (F, 50% methylated), and PWS patients (᭜, 100% methylated) as template. qOSMA is insensitive to changes in DNA concentration yet requires a minimal amount of endonuclease when analyzing low methylation levels. Note that the x axis scales for (A) and (B) are logarithmic. FDU, FastDigest units.
DNA concentrations did not change the values for the methylation measurements appreciably, but a slight decrease in assay precision was observed. Varying the HpaII concentration, on the other hand, had a substantial influence on methylation measurements, with an exponential relationship between the restriction enzyme concentration and the proportion of digested DNA molecules. Methylation states expected to be 0% produced measurements of 24.5%-1.14% with 0.0625-2 U of HpaII. On the other hand, DNA methylation measurements were correct at expected methylation levels of 50% and 100% (Fig. 3B) .
Assay performance depended on DNA quality such that old DNA samples that were not reextracted showed aberrantly high methylation levels, which indicated inhibition of the HpaII enzyme (Fig. 2B) . Therefore, we evaluated the suitability of the CFTR assay to detect induction of enzyme inhibition by low-quality DNA. We found a significant correlation (Kendall ϭ 0.767; P Ͻ 10
Ϫ5
; Fig. 2B ) between measured CFTR and SNRPN methylation levels in AS samples, demonstrating that the effect of HpaII inhibition is almost the same for the CFTR and SNRPN assays. This finding confirms the ability of CFTR to survey for complete DNA digestion. The CFTR methylation levels measured in AS samples, however, were higher than those for SNRPN (P Ͻ 0.001, paired Wilcoxon signed rank test) because of increased formation of side products in the CFTR assay. Finally, a strong correlation between the measured methylation level and the intensity of DNA shearing (Kendall ϭ 0.905; P Ͻ 0.01) indicated a significant influence of DNA molecular weight on digestibility.
To assess assay repeatability, we analyzed a sample from an unaffected control individual 7 times for each of the different HpaII and qPCR reagent batches. At a 60°C annealing temperature, we obtained a median measured methylation level of 50.5% (range, 47.6%-53.4%) for SNRPN and 5.5% (range, 3.1%-8.4%) for CFTR.
The qPCR efficiencies for the SNRPN and CFTR assays were 2.12 and 2.04, respectively, as determined by the calibration curve method with sham reactions with serially diluted genomic DNA (29 ) . In addition, SNRPN HpaII and sham reactions with serial dilutions of PWS DNA-which is fully methylated at the SNRPN locus and thus unaffected by digestion-indicated that the qPCR efficiencies in the HpaII and sham reactions are equal (i.e., the difference in efficiency, ⌬E, is 0.006).
BLINDED ANALYSIS OF PWS PATIENTS, AS PATIENTS, AND UNAFFECTED CONTROLS
In all 35 samples investigated, SNRPN methylation was unambiguously assigned according to the diagnostic criteria defined in the data-analysis section. For the SNRPN locus, the median methylation level was 101.4% (range, 92.0%-103.5%; n ϭ 12) in PWS patients, 3.9% (range, 1.0 -6.7%; n ϭ 12) in AS patients, and 52.1% (range, 48.3%-60.1%; n ϭ 11) in the Quantitative 1-Step DNA Methylation Analysis healthy control individuals. The median methylation value in the CFTR assay was 6.9% (range, 1.6%-12.7%; n ϭ 35) (Fig. 4A) .
Similarly, copy number status was correctly determined in all samples. A ratio of 0.69 in 1 sample was not within the required range, and a second experiment was needed to confirm a deletion. This imprecision is presumably attributable to DNA sample inhomogeneity, as indicated by a high divergence in the C q values in reaction replicates of this sample. Patients with UPD as well as healthy controls presented with a median SNRPN copy number ratio of 0.98 (range, 0.87-1.09; n ϭ 16), whereas patients with deletions showed a median ratio of 0.47 (range, 0.40 -0.62; n ϭ 19) (Fig. 4B) .
CORRECTION FOR INCOMPLETE DIGESTION
To further evaluate the potential of correction, we applied Eq. 5 to the DNA samples for the blinded analysis of PWS patients, AS patients, and unaffected controls. In addition, we performed a correction for samples that showed partly reduced digestion. These old DNA samples were not reextracted and showed a median CFTR methylation level of 22.4% (range, 4.3%-40.1%). The median of the respective AS samples was used as the calibrator quotient (MM SNRPNcal / MM CFTRcal ). The correction increased assay accuracy in both types of DNA samples, in that measured SNRPN levels were significantly (P Ͻ 0.05) closer to the expected values. In addition, correction decreased assay variance in AS samples (Table 1) . Increased concordance with expected values and precision allowed proper discrimination between AS and PWS patients and unaffected controls, even in samples with reduced digestibility. Without correction, an AS sample was classified as being from an unaffected control individual, and 5 other samples were out of the defined ranges.
With correction, all samples were within the defined ranges, and diagnosis was unambiguous in each case (Fig. 5) . 
Discussion
We present a qOSMA, the first single-step DNA methylation assay that uses untreated genomic DNA as template. It is based on qPCR reactions containing methylation-sensitive endonucleases, which allow DNA digestion and subsequent quantification to be carried in a single work step through selection of the appropriate reaction conditions. The assay includes sham reactions containing no endonuclease to correct for variation in DNA input, allowing assessment of the degree of methylation via quantification of the cut (and thus unmethylated) DNA molecules. In addition, sham reactions can be used for simultaneously quantifying copy number, which adds important information regarding the potential causes of aberrant methylation at the investigated locus. Besides the evident reduction in workload, our procedure substantially lowers the risk of errors due to handling and pipetting by reducing the methylation analysis to a single step, which is a crucial condition in diagnostics. Given that most endonucleases are fully active in a PCR mix (http://www.neb. com/nebecomm/tech_reference/restriction_enzymes/ activity_in_taqPCRmix.asp), our assay is presumably applicable to most CpG sites for which methylationsensitive or -specific endonucleases are available.
In the current study, we evaluated our novel assay with a blinded diagnostic approach that included 12 PWS and 12 AS patients, as well as 11 unaffected control individuals. All samples were unambiguously assigned to the correct methylation and copy number status, with the exception of a sample from 1 individual that required a repeat analysis to confirm a deletion at the SNRPN locus. During assay evaluation, we found a linear relationship between the expected and measured levels of DNA methylation ( Fig. 2A) , demonstrating the quantitative nature of our assay. Considering the precision of the assay, we suppose that it even has the potential to detect mosaicisms in PWS and AS patients (16 ). It is not able to distinguish UPDs from imprinting defects, however; such differentiation will require additional steps, such as microsatellite analysis.
DNA from phage, which has been proposed as a control for proper DNA digestion, is typically spiked into the investigated DNA sample and analyzed in parallel with the locus of interest (14 ) . Extrinsic DNA molecules, however, may respond differently to treatments than genomic loci and therefore cannot be used to normalize for genomic DNA input in copy number analysis. We thus investigated the potential of the CFTR promoter to serve as a control for DNA digestibility. The CFTR promoter has been reported to be unmethylated in several tissues (21 ) , and deletions in the promoter that could invalidate a copy number analysis are extremely rare (http://www3.genet.sickkids.on.ca/cftr/ app). We found that the CFTR assay reliably detects reduced DNA digestion, making this assay a valuable alternative to spiking with extrinsic DNA-particularly considering its concomitant qualification for serving as a reference in copy number quantification.
In some instances, it might be of interest not only to detect but also to correct for incomplete DNA digestion, e.g., when investigating large numbers of samples with reduced DNA digestibility, for which reextraction might not be feasible. Correction of DNA samples with typical, as well as reduced, digestibility with Eq. 5 substantially increased assay concordance with expected values and precision, suggesting that the proposed model is well suited for bias correction and provides a useful tool for retrospective studies of DNA samples of varying quality.
DNA quality is not an issue when extracting DNA with silica-based kits, because all samples (re)extracted with this technique performed well. Because the digestibility of DNA is decreased with DNA of reduced molecular weight, however, we do not recommend shearing of DNA before digestion, as has been proposed (13 ) .
A critical assay parameter is the appearance of qPCR side products that might form at low methylation levels because of the absence of appropriate templates. The annealing temperature of the CFTR assay was decreased from 65°C to 60°C in the blinded analysis of PWS and AS samples. On the one hand, this reduction in temperature allowed PWS/AS diagnosis to be performed in a single LightCycler run; on the other hand, it led to an increased formation of side products that led to an overestimate of CFTR methylation. Thus, the formation of side products has to be strictly monitored when analyzing low-level methylation. In addition, positional effects due to incomplete DNA denaturation could reduce assay precision on plate-based instruments, but not on properly used capillary-based instruments (26 ) . We are currently preparing a manuscript that shows how to detect and circumvent such positional effects on plate-based qPCR instruments.
In summary, we have presented the first assay for qOSMA analysis. The quantitative assay is performed in a closed tube, substantially reduces the hands-on time, and can be accomplished within 1.5 h after DNA extraction. It thus strongly facilitates high-throughput methylation analyses and is feasible in any laboratory equipped with a qPCR instrument. Finally, the assay allows simultaneous quantification of DNA methylation and copy number. It therefore qualifies as an efficient diagnostic tool for PWS, AS, and any other imprinting disorder, as well as for other methylationsensitive diseases, such as different forms of cancer.
